Skip to main content

Advertisement

Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Recent advances in nanotheranostics for triple negative breast cancer treatment

Fig. 3

Brief representation of potential inhibitors of various pathways and receptors for the treatment of triple-negative breast cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors like BSI-20I target ssDNA break repairing enzyme causing synthetic lethality resulting in control of cancer cell proliferation. Similarly, other class of inhibitors like tyrosine kinase (TK), EGFR, PI3K, angiogenesis, insulin-like growth factor (IGF), heat shock protein (Hsp90), histone deacetylase (HDAC), andmammalian target of rapamycin (mTOR) employ different mechanism to control and treat TNBC.

Back to article page